Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccine

JAMA

Volumn 307, Issue 8, 2012, Pages 804-812

  Smith, Kenneth J ^a   Wateska, Angela R ^a   Nowalk, Mary Patricia ^a   Raymund, Mahlon ^a   Nuorti, J Pekka ^b,c   Zimmerman, Richard K ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^c TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

PNEUMOCOCCUS VACCINE; 13 VALENT PNEUMOCOCCAL VACCINE; 13-VALENT PNEUMOCOCCAL VACCINE; 23 VALENT PNEUMOCOCCAL CAPSULAR POLYSACCHARIDE VACCINE; 23-VALENT PNEUMOCOCCAL CAPSULAR POLYSACCHARIDE VACCINE; VACCINE;

ADULT; AGED; ARTICLE; BACTERIUM CONJUGATION; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFECT; DRUG EFFICACY; HERD IMMUNITY; HUMAN; INFECTION PREVENTION; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; VACCINATION; COHORT ANALYSIS; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; DECISION SUPPORT SYSTEM; ECONOMICS; MIDDLE AGED; PROBABILITY; STREPTOCOCCUS PNEUMONIA;

AGED; COHORT STUDIES; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; HUMANS; MARKOV CHAINS; MIDDLE AGED; PNEUMOCOCCAL VACCINES; PNEUMONIA, PNEUMOCOCCAL; QUALITY-ADJUSTED LIFE YEARS; VACCINATION; VACCINES, CONJUGATE;

EID: 84863393658     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2012.169     Document Type: Article

References (49)

1. Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR Morb Mortal Wkly Rep. 2010;59(34): 1102-1106.
2. Jackson LA, Janoff EN. Pneumococcal vaccination of elderly adults: new paradigms for protection. Clin Infect Dis. 2008;47(10):1328-1338.
3. Metersky ML, Dransfield MT, Jackson LA. Determining the optimal pneumococcal vaccination strategy for adults: is there a role for the pneumococcal conjugate vaccine? Chest. 2010;138(3):486-490.
4. Huss A, Scott P, Stuck AE, Trotter C, Egger M. Efficacy of pneumococcal vaccination in adults: a meta-analysis. CMAJ. 2009;180(1):48-58.
5. Moberley SA, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev. 2008;(1): CD000422.
6. Grijalva CG, Nuorti JP, Arbogast PG, Martin SW, Edwards KM, Griffin MR. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a timeseries analysis. Lancet. 2007;369(9568):1179-1186. (Pubitemid 46527876)
7. Simonsen L, Taylor RJ, Young-Xu Y, Haber M, May L, Klugman KP. Impact of pneumococcal conjugate vaccination of infants on pneumonia and influenza hospitalization and mortality in all age groups in the United States. MBio. 2011;2(1):e00309-e00310.
8. Lexau CA, Lynfield R, Danila R, et al Active Bacterial Core Surveillance Team. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA. 2005;294(16):2043-2051. (Pubitemid 41539937)
9. Pilishvili T, Lexau C, Farley MM, et al Active Bacterial Core Surveillance/Emerging Infections Program Network. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 2010;201(1):32-41.
10. Centers for Disease Control and Prevention (CDC). Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children: Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep. 2010;59(9):258-261.
11. Nuorti JP, Whitney CG; Centers for Disease Control and Prevention (CDC). Prevention of pneumococcal disease among infants and children: use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2010; 59(RR-11):1-18.
12. Fry AM, Zell ER, Schuchat A, Butler JC, Whitney CG. Comparing potential benefits of new pneumococcal vaccines with the current polysaccharide vaccine in the elderly. Vaccine. 2002;21(3-4):303-311. (Pubitemid 35346825)
13. Black SB, Shinefield HR, Ling S, et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr Infect Dis J. 2002; 21(9):810-815.
14. Hak E, Grobbee DE, Sanders EA, et al. Rationale and design of CAPITA: a RCT of 13-valent conjugated pneumococcal vaccine efficacy among older adults. Neth J Med. 2008;66(9):378-383.
15. Approved products: Prevnar 13. US Food and Drug Administration. http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm201667. htm. Accessed February 1, 2012.
16. Self-reported pneumococcal vaccination coverage trends 1989-2008 among adults by age group, risk group, race/ethnicity, health-care worker status, and pregnancy status, United States, National Health Interview Survey (NHIS). Centers for Disease Control and Prevention. http://www.cdc.gov/flu/professionals /vaccination/pdf/NHIS89-08ppvvaxtrendtab.pdf. Accessed January 25, 2012.
17. Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996.
18. Zimmerman RK, Lauderdale DS, Tan SM, Wagener DK. Prevalence of high-risk indications for influenza vaccine varies by age, race, and income. Vaccine. 2010; 28(39):6470-6477.
19. Goldberg RJ, Larson M, Levy D. Factors associated with survival to 75 years of age in middle-aged men and women: the Framingham Study. Arch Intern Med. 1996;156(5):505-509. (Pubitemid 26077352)
20. Ho KK, Anderson KM, Kannel WB, Grossman W, Levy D. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation. 1993;88(1):107-115. (Pubitemid 23195439)
21. Kannel WB, D'Agostino RB, Silbershatz H, Belanger AJ, Wilson PW, Levy D. Profile for estimating risk of heart failure. Arch Intern Med. 1999;159(11):1197-1204. (Pubitemid 29269859)
22. Kannel WB, Vokonas PS. Demographics of the prevalence, incidence, and management of coronary heart disease in the elderly and in women. Ann Epidemiol. 1992;2(1-2):5-14.
23. SEER age-specific cancer incidence, all sites. Surveillance Research Program, National Cancer Institute. http://seer.cancer.gov/faststats/sites.php. Accessed January 25, 2012.
24. Arias E. United States life tables, 2006. Natl Vital Stat Rep. 2010;58(21):1-40.
25. Carbonara S, Monno L, Longo B, Angarano G. Community-acquired pneumonia. Curr Opin Pulm Med. 2009;15(3):261-273.
26. Trends in pneumonia and influenza morbidity and mortality. American Lung Association. http://www.lungusa.org/finding-cures/our-research /trend-reports/pi-trend-report.pdf. Accessed January 25, 2012.
27. Rubin JL, McGarry LJ, Strutton DR, et al. Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States. Vaccine. 2010;28(48):7634-7643.
28. Weycker D, Strutton D, Edelsberg J, Sato R, Jackson LA. Clinical and economic burden of pneumococcal disease in older US adults. Vaccine. 2010;28(31): 4955-4960.
29. Smith KJ, Zimmerman RK, Lin CJ, et al. Alternative strategies for adult pneumococcal polysaccharide vaccination: a cost-effectiveness analysis. Vaccine. 2008;26(11):1420-1431.
30. Wyrwich KW, Fihn SD, Tierney WM, Kroenke K, Babu AN, Wolinsky FD. Clinically important changes in health-related quality of life for patientswith chronic obstructive pulmonary disease: an expert consensus panel report. J Gen Intern Med. 2003;18(3):196-202. (Pubitemid 36399456)
31. Fine MJ, Stone RA, Singer DE, et al. Processes and outcomes of care for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team (PORT) cohort study. Arch Intern Med. 1999;159(9):970-980. (Pubitemid 29222498)
32. Jackson LA, Benson P, Sneller VP, et al. Safety of revaccination with pneumococcal polysaccharide vaccine. JAMA. 1999;281(3):243-248. (Pubitemid 29058113)
33. Gold MR, Franks P, McCoy KI, Fryback DG. Toward consistency in cost-utility analyses: using national measures to create condition-specific values. Med Care. 1998;36(6):778-792. (Pubitemid 128454315)
34. Sisk JE, Whang W, Butler JC, Sneller VP, Whitney CG. Cost-effectiveness of vaccination against invasive pneumococcal disease among people 50 through 64 years of age: role of comorbid conditions and race. Ann Intern Med. 2003;138(12):960-968.
35. CDC vaccine price list. Centers for Disease Control and Prevention. http://www.cdc.gov/vaccines /programs/vfc/cdc-vac-price-list.htm. Accessed January 25, 2012.
36. Medicare Physician Fee Schedule look-up (CPT 90471). Data year: 2006. http://www.cms.gov/apps /physician-fee-schedule/. Accessed November 16, 2010.
37. Healthcare Cost & Utilization Project (HCUP). Agency for Healthcare Research and Quality. http: //www.ahrq.gov/data/hcup/. Accessed January 25, 2012.
38. Hausdorff WP, Feikin DR, Klugman KP. Epidemiological differences among pneumococcal serotypes. Lancet Infect Dis. 2005;5(2):83-93. (Pubitemid 40174779)
39. Lu PJ, Nuorti JP. Pneumococcal polysaccharide vaccination among adults aged 65 years and older, US, 1989-2008. Am J Prev Med. 2010;39(4):287-295.
40. National population estimates for the 2000s. US Census Bureau. http://www.census.gov/popest /data/national/asrh/2006/files/NC-EST2006 -ALLDATA-R-File14.dat. Accessed January 30, 2012.
41. Cantor SB. Cost-effectiveness analysis, extended dominance, and ethics: a quantitative assessment. Med Decis Making. 1994;14(3):259-265. (Pubitemid 24206351)
42. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? tentative guidelines for using clinical and economic evaluations. CMAJ. 1992; 146(4):473-481.
43. Braithwaite RS, Meltzer DO, King JT Jr, Leslie D, Roberts MS. What does the value of modern medicine say about the $50,000 per quality-adjusted lifeyear decision rule? Med Care. 2008;46(4):349-356.
44. Fiore AE, Uyeki TM, Broder K, et al Centers for Disease Control and Prevention (CDC). Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep. 2010; 59(RR-8):1-62.
45. Cutts FT, Zaman SM, Enwere G, et al Gambian Pneumococcal Vaccine Trial Group. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in the Gambia: randomised, double-blind, placebo-controlled trial. Lancet. 2005;365(9465): 1139-1146. (Pubitemid 40417563)
46. Hansen J, Black S, Shinefield H, et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than 5 years of age for prevention of pneumonia: updated analysis using World Health Organization standardized interpretation of chest radiographs. Pediatr Infect Dis J. 2006;25 (9):779-781. (Pubitemid 44325778)
47. Klugman KP, Madhi SA, Huebner RE, Kohberger R, Mbelle N, Pierce N; Vaccine Trialists Group. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med. 2003;349(14):1341-1348. (Pubitemid 37186212)
48. Millar EV, Watt JP, Bronsdon MA, et al. Indirect effect of 7-valent pneumococcal conjugate vaccine on pneumococcal colonization among unvaccinated household members. Clin Infect Dis. 2008;47(8): 989-996.
49. Huang SS, Johnson KM, Ray GT, et al. Healthcare utilization and cost of pneumococcal disease in the United States. Vaccine. 2011;29(18):3398-3412.